IRIS
NECCHI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.345
AS - Asia 7.165
NA - Nord America 4.647
SA - Sud America 2.208
AF - Africa 169
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 10
Totale 21.559
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.363
RU - Federazione Russa 4.298
SG - Singapore 2.655
CN - Cina 1.920
BR - Brasile 1.810
HK - Hong Kong 1.107
SE - Svezia 917
VN - Vietnam 699
IT - Italia 503
DE - Germania 361
FR - Francia 350
RO - Romania 267
BD - Bangladesh 226
AR - Argentina 155
IN - India 155
CA - Canada 135
GB - Regno Unito 135
FI - Finlandia 121
AT - Austria 109
MX - Messico 87
IQ - Iraq 61
PL - Polonia 61
ID - Indonesia 58
ZA - Sudafrica 57
NL - Olanda 56
EC - Ecuador 54
JP - Giappone 54
ES - Italia 45
CO - Colombia 42
IE - Irlanda 36
TR - Turchia 36
VE - Venezuela 34
PY - Paraguay 33
CL - Cile 31
UA - Ucraina 25
PK - Pakistan 24
MA - Marocco 22
TN - Tunisia 22
PE - Perù 20
UY - Uruguay 18
UZ - Uzbekistan 17
MY - Malesia 16
EG - Egitto 15
SA - Arabia Saudita 15
NP - Nepal 14
AU - Australia 13
KE - Kenya 13
LT - Lituania 13
JM - Giamaica 11
AZ - Azerbaigian 10
IR - Iran 10
PH - Filippine 10
DO - Repubblica Dominicana 9
DZ - Algeria 9
NI - Nicaragua 9
AE - Emirati Arabi Uniti 8
EU - Europa 8
JO - Giordania 8
SN - Senegal 8
LB - Libano 7
NG - Nigeria 7
BB - Barbados 6
BE - Belgio 6
BH - Bahrain 6
BO - Bolivia 6
KR - Corea 6
KW - Kuwait 6
KZ - Kazakistan 6
BG - Bulgaria 5
IL - Israele 5
PA - Panama 5
PT - Portogallo 5
AL - Albania 4
CI - Costa d'Avorio 4
GT - Guatemala 4
KH - Cambogia 4
MD - Moldavia 4
PR - Porto Rico 4
TT - Trinidad e Tobago 4
BA - Bosnia-Erzegovina 3
BN - Brunei Darussalam 3
CR - Costa Rica 3
CZ - Repubblica Ceca 3
ET - Etiopia 3
GR - Grecia 3
GY - Guiana 3
HN - Honduras 3
HU - Ungheria 3
KG - Kirghizistan 3
LY - Libia 3
OM - Oman 3
SK - Slovacchia (Repubblica Slovacca) 3
TH - Thailandia 3
AO - Angola 2
BY - Bielorussia 2
CH - Svizzera 2
CY - Cipro 2
GE - Georgia 2
QA - Qatar 2
SR - Suriname 2
Totale 21.538
Salva come PNG Salva come JPEG
Città #
Singapore 1.218
Hong Kong 1.099
Moscow 950
Ashburn 639
Dallas 572
San Jose 504
Shanghai 425
Hefei 345
Lawrence 302
Princeton 302
Lauterbourg 288
Ho Chi Minh City 285
New York 235
Beijing 226
São Paulo 165
Hanoi 151
Los Angeles 140
Milan 116
Nuremberg 113
Boardman 96
Santa Clara 83
Helsinki 70
Rio de Janeiro 67
Rome 62
Munich 61
Orem 53
Montreal 46
Warsaw 45
Tokyo 43
Vienna 41
Belo Horizonte 37
Frankfurt am Main 36
Turku 36
Brasília 35
Da Nang 34
Dublin 34
Brooklyn 33
Chennai 31
Denver 31
Haiphong 31
Houston 28
Mexico City 28
Atlanta 27
Guangzhou 27
Toronto 27
Phoenix 26
Poplar 26
Porto Alegre 26
Chicago 24
Council Bluffs 24
Johannesburg 24
Campinas 23
Mumbai 23
Salvador 23
London 22
Pune 22
Turin 21
Curitiba 20
Stockholm 20
Amsterdam 19
Biên Hòa 18
Buffalo 17
Caxias do Sul 17
Erbil 17
Manchester 17
Columbus 16
Recife 16
Tashkent 16
Washington 16
Baghdad 15
Bogotá 15
Dhaka 15
Hangzhou 15
Hải Dương 15
Seattle 15
Sorocaba 15
Tianjin 15
Fortaleza 14
Guayaquil 14
Kassel 14
Lappeenranta 14
Manaus 14
Montevideo 14
Quito 14
Ankara 13
Buenos Aires 13
Charlotte 13
Guarulhos 13
Ribeirão Preto 13
The Dalles 13
Asunción 12
Goiânia 12
Lima 12
Nairobi 12
Osasco 12
Santo André 12
Thái Bình 12
Thái Nguyên 12
Can Tho 11
Caracas 11
Totale 10.124
Salva come PNG Salva come JPEG
Nome #
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors 388
[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab 209
A comprehensive assessment of frailty status on surgical, functional and oncologic outcomes in patients treated with partial nephrectomy––A large, retrospective, single-center study 169
A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02 160
Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard 148
Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: A systematic review and meta-analysis 143
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis 138
Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review 138
A global approach to improving penile cancer care 136
Neglected lymph nodal metastases in patients with renal cancer: when to extend the anatomical template of lymph node dissection during nephrectomy 134
Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer 134
Accuracy of Transurethral Resection of the Bladder in Detecting Variant Histology of Bladder Cancer Compared with Radical Cystectomy 132
Preoperative risk calculator for the probability of completing nephron sparing for kidney cancer 129
A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings 128
Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study 126
Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence 123
Clinical, pathological and long-term oncologic outcomes of papillary type I vs. type II renal cell carcinoma 123
Use of 18F-fluoro-2-deoxy-d-glucose (18F-FDG) PET/CT for lymph node assessment before radical cystectomy in bladder cancer patients 122
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation 122
How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most? 119
Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma 119
Pulmonary lesion after surgery for renal cancer: progression or new primary? 118
Long-term functional outcomes in patients undergoing radical nephrectomy for renal cell carcinoma and tumor thrombus 118
A risk calculator predicting recurrence in lymph node metastatic penile cancer 116
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 115
Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆ 114
Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma 112
Immunotherapy in advanced kidney cancer: an alternative meta-analytic method using reconstructed survival data in case of proportional hazard assumption violation 111
Causal contributors to tissue stiffness and clinical relevance in urology 111
Re: Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-Invasive Bladder Carcinoma with Variant Histologies 109
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study) 109
Contemporary Treatment Patterns and Outcomes for Patients with Penile Squamous Cell Carcinoma: Identifying Management Gaps to Promote Multi-institutional Collaboration 108
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma 107
Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer 104
ASSOCIATION BETWEEN BRCA 1/2 POLYMORPHISMS AND DISEASE AGGRESSIVENESS IN A PROSPECTIVE COHORT OF PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY 104
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis 103
Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent 103
Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy 103
Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial 103
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial 102
Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study 100
[The treatment of early-stage germ cell tumors of the testis (GCTT)]. [Il trattamento dei Tumori Germinali del Testicolo (TGT) in fase iniziale.] 100
Bladder-sparing combination treatments for muscle-invasive bladder cancer: A plea for standardized assessment and definition of clinical trials endpoints 100
ASSOCIATION BETWEEN POLYMORPHISMS OF HOMOLOGOUS RECOMBINATION RAD51B AND DISEASE RECURRENCE IN A PROSPECTIVE COHORT OF PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY 99
Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial 99
Von Hippel-Lindau disease-associated renal cell carcinoma: a call to action 98
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor beta (TGF beta) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial 97
An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer 97
Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma 97
Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study 96
Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies 96
Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab? 95
Multidisciplinary management of patients diagnosed with von Hippel-Lindau disease: A practical review of the literature for clinicians 94
Re: Siamak Daneshmand, Azadeh Nazemi. Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence. Eur Urol Focus 2020;6:639–41 93
High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors? 90
Evaluation of cognitive function in trials testing new-generation hormonal therapy in patients with prostate cancer: A systematic review 88
The obesity paradox in metastatic castration-resistant prostate cancer 88
A Plea for Economically Sustainable Evidence-based Guidelines 87
Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration 86
Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand? 86
Topographic modification of the extracellular matrix precedes the onset of bladder cancer 85
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial 85
Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer 85
Adjuvant Systemic Therapy for High-risk Muscle-invasive Bladder Cancer After Radical Cystectomy: Current Options and Future Opportunities 85
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression 84
A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors 84
Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study 83
Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial 81
Adjuvant Therapy in Nonmetastatic High-risk Kidney Cancer: Importance of the Timing of Postnephrectomy Imaging and Treatment Delivery 80
Immunohistochemistry to Enhance Prognostic Allocation and Guide Decision-Making of Patients With Advanced Urothelial Cancer Receiving First-Line Chemotherapy 80
Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty 79
Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer 79
Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center 78
Sex-specific Alterations in the Urinary and Tissue Microbiome in Therapy-naïve Urothelial Bladder Cancer Patients 78
Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology–Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration 77
Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure 76
Penile cancer 76
Risk factors and survival outcomes for upstaging after inguinal lymph node dissection for cN1 penile squamous cell carcinoma 75
A Prognostic Model Including Pre- and Postsurgical Variables to Enhance Risk Stratification of Primary Mediastinal Nonseminomatous Germ Cell Tumors: The 27-Year Experience of a Referral Center 75
An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis 75
Administration of high-dose chemotherapy with stem cell support in patients 40 years of age or older with advanced germ cell tumours: a retrospective study from the European Society for Blood and Marrow Transplantation database 75
Penile cancer 74
Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database 73
A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy? 72
Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma 71
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial 70
Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes(dagger) 69
Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma 69
Reliability of Serum Tumor Marker Measurement to Diagnose Recurrence in Patients with Clinical Stage I Nonseminomatous Germ Cell Tumors Undergoing Active Surveillance: A Systematic Review 69
Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors 69
Immune-based therapies in penile cancer 68
Targetable gene fusions and aberrations in genitourinary oncology 68
The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial 67
Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage i nonseminomatous germ cell tumours: Long-term outcome and analysis of risk factors of recurrence 67
Teratoma With Somatic-Type Malignant Components in Germ Cell Tumors of the Testis: A Clinicopathologic Analysis of 40 Cases With Outcome Correlation 67
Neoadjuvant chemotherapy for lymph node-positive penile cancer: Current evidence and knowledge 67
The Leydig cell tumour Scaled Score (LeSS): a method to distinguish benign from malignant cases, with additional correlation with MDM2 and CDK4 amplification 67
Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy 67
Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis 66
Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI 66
Totale 10.077
Salva come PNG Salva come JPEG
Categoria #
all - tutte 143.592
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 143.592
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022270 0 53 3 101 1 8 13 10 13 11 4 53
2022/20231.668 675 354 123 38 18 233 47 94 48 5 15 18
2023/2024934 23 57 65 63 79 182 132 118 7 20 44 144
2024/20254.910 602 94 75 78 84 350 861 490 861 739 292 384
2025/202613.960 1.026 1.134 972 1.997 967 367 1.063 944 3.794 728 534 434
Totale 21.995